PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

Under the Paperwork F	Reduction Act of 1995, no persons are required to	U.S. Patent and Trader respond to a collection of information	mark Office; U.S. DEF tion unless it contains	PARTMENT OF COMM a valid OMB control no	ERC ımbe
Substitute for form 14		Coi	mplete if Knov	אוף חיי	$\overline{}$
		Application Number	10/729,156	/ ~	77
INCODIA	TION DISCLOSURE	Filing Date	12/05/2003	Je MAR o	\$
		First Named Inventor	Wang et al.	2000	4
STATEME	NT BY APPLICANT	Art Unit	1614	7	4./
(Use as	many sheets as necessary)	Examiner Name	Hui	34m . of	?
Chant 1	of	Attorney Docket Number	UM-08477	EMARK	

Examiner	Cite No.1	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
Initials* No.	No.'	Number-Kind Code ^{2 (F known)}	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
		US-			

		FORE	IGN PATENT DOCU			_
Examiner nitials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	١.
		Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	
/SH/	1	CN 1406919 /	09/06/2001		entire document	L
	2	CN 87105990 <	12/26/1987		entire document	
	3	CN 1033795	12/07/1989		entire document	L
\neg	4	CN 1094392 .	11/02/1994		entire document	Г
	-5-	DE 1917341 /			entire document	t
7/	6	JP 01132542	04/03/1969		entire document	Г

06/18/2007 /San Ming Hui/ Considered Signatura

**EXAMMER: Initial # interence considered, whether or not classion is in conformance with MPEP 609, Draw lins through citation if not in conformance and not considered. Include copy of this form with nast communication to applicant. *Applicants unique clasted netspassion number (options). *See Kinds Codes of USPTO Patent Documents at www.useriop over or MPEP 90.0 in .* Enter Office that issued the document, by the No-electer code (WIPO Standard ST.s). *For Topical Provider to the provider of the provider of the patent of the pat Translation is attached.

Inansation is attached.

This collection of Inmassion is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain about 10 yr to profit which is fire [and by his USFT 0.00 process) an application. Confidentially is governed by 38 U.S.C. 122 and 970. The wall large depending upon the individual case. Any comments to complete, the confidential or the profit of the prof

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08A (08-03)

Approved for use through 07/31/2006, OMB 0551-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Fradewind Cheek U.S. Patent and Fradewind Chee

Attorney Docket Number UM-08477 Sheet 2 of U. S. PATENT DOCUMENTS Name of Patentee or Pages, Columns, Lines, Where **Publication Date** Examiner Document Number MM-DD-YYYY Applicant of Cited Document Relevant Passages or Relevant Figures Appear Number-Kind Code^{2 (F known)} IIS. US-USus. 110 US-IIS. US. US-US-US-US-

FOREIGN PATENT DOCUMENTS Foreign Patent Document Name of Patentee or Pages, Columns, Lines, Date Applicant of Cited Document Where Relevant Passages Initiale Or Relevant Figures Appear MM-DD-YYYY Country Code³ "Number ⁴ "Kind Code⁵ (if known) entire decriffent 7 RU 2067111 entire document 8 SU 212245 SU 222042 entire document q

Examiner Signature	/San Ming Hui/	Date Considered	06/18/2007

EXAMINER: Initial if reference considered, whether or not distion is in conformance with JIMPEP 699. Draw him through distint for in conformance and not considered, include copy of this form with next communication to applicant. Applicants variety exclude designation recognition in "See Kinds Codes of USP10 Parall Draw Comment as the exception over of the Post of the Codes of Comment as the exception over of the Post of the Codes of Codes of the Post of the Codes of Codes of the Post of the Codes of Codes of the Post of the Post of the Post of the Codes of the Post of the

This collection of information is required by 37 CFR 197 and 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the collection) are application. Confederably is governed by 35 U.S. C. 122 and 37 CFR 1.41. This collection is estimated to take 2 hours to complete benefit or produced by the complete produced application form to the USPTO. Time will vary depending upon the individual case. Any common on the amount of time you require to complete this form ander suppressions for reducing this butter, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Dox 1450, Alexandria, Wx 2213-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEMO

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons ar		n of information unless it contains a valid OMB control number Complete if Known
Substitute for form 1449/PTO	Application Number	10/729,156
INFORMATION DISCLOSURE	Filing Date	12/05/2003
STATEMENT BY APPLICANT	First Named Inventor	Wang et al.
(Use as many sheets as necessary)	Art Unit	1614
(Use as many sneets as necessary)	Examiner Name	Hui

Attorney Docket Number

UM-08477

Sheet 3

of

			NON PATENT LITERATURE DOCUMENTS	
Examir Initials		Cite No. ¹		
/SI	4/	10	Becattini et al., Rational Design and Real Time, In-Cell Detection of the Proapoptotic Activity of a Novel Compound Targeting Bcl-XL; Chem Biol 11:389 (2004)	
		11	Brzezinski et al., Selective Esterification of Gossypol by Copper Acetate in Acetonitrile-Spectroscopi Studies; Spectroscopy Lett 27:1143 (1994)	
		12	Dowd et al., Crystal and Molecular Structure of an Enantiomeric Gossypol-Acetic Acid Clathrate; J am Oil Chem Soc 76:1343 (1999)	
		13	Dowd et al., A Correction to the Molecular Structure of Enantiomeric Gossypol; J Am Oil Chem Soc 78:1171 (2001)	
		14	Dowd et al., The Gossypol-Cyclododecanone (1/2) inclusion Complex; Acta Crystallogr C 59:397 (2003)	
Dowd et al., The (-) –Gossypol-2,4-pentanedione (1:2) inclusion complex; J Chem Crystallogr 34:559 (2004)		/		
		16	Freedman et al., Determination of the Absolute Configuration and Solution Conformation of Gossypol by Vibrational Circular Dichroism; Chirality 15:196 (2003)	1
		17	Gdaniec et al., Gossypol; Compregensive Supramolecular Chemistry6:117-200	<u> </u>
		18	Gonzalez Correa et al., New Gossypol Derivatives; J Am Oil Chem Soc 43: 678 (1966)	
J	/	19	Han, X Y Jie He Za Zhi 2:159 (1982 (Chinese)	

Examiner Signature	/San Ming Hui/	Date Considered	06/18/2007
*FXAMINER: In	itial if reference considered, whether or not citation is in conformance with MPEP 60	9. Draw line through o	itation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

considered, include copy of this form with next communication to appropriate.

1 Applicants rules (see Lection designation number (optional). Applicant is the place a check make here if English Inspuage Transistion is attached.

This collection of information is required by 30 cmm of the place of the place and the place of the place and place which is to file (and by the USPTO Time of the place). The collection is estimated to take 2 hours and place of the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006, OMB 0651-0031

Under the Paperwork	Reduction Ac	t of 1995, no persons a		of information unless it contains a valid OMB control number.
ubstitute for form 1449/PT	·O			Complete if Known
abstate for form 1445/11	Ü		Application Number	10/729,156
NFORMATIC	N DIS	CLOSURE	Filing Date	12/05/2003
STATEMENT	BY A	PPLICANT	T First Named Inventor Wang etal.	Wang etal.
(Use es many			Art Unit	1614
(Ose es many	sneets as n	ecessary)	Examiner Name	Hui
neet 4	of		Attorney Docket Number	UM-08477

Sheet 4

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or oountry where published	T²
/SH/ 20		Hei et al., Electron Microscope Examination of Biopsy of Testis Tissue from the Patients with Tumors after Oral Treatment with Gossypot, Acta Acad Med Sinicae 61:527 (1981) (Chinese with Translation)	/.
	21	Jaroszewski et al., Effects of Gossypol on Drug-Sensitive and Drug-Resistant Cancer Cells; Proc Am Assoc Cancer Res 31:377 (1990)	
	22	Kable et al., Potency, Selectivity and Cell Cycle Dependence of Catechols in Human Tumour Cells In Vitro; Biochem Pharmacol 37:1711 (1988)	
	23	Kim et al., Gossypol, a Hyperthermic Sensitizer of HeLa Cells; Cancer Res 45:6338 (1985)	
	24	Liu et al., The (-)-Enantiomer of Gossypol Possesses Higher Anticancer Potency than Racemic Gossypol in Human Breast Cancer; Ancticancer Res 22:33 (2002)	
	25	McClarty et al., Ribonucleotide Reductase: A Intracellular Target for the Male Antifertility Agent, Gossypol; Biochem Biophys Res Commun 133:300 (1985)	
	26	Miller et al., Structure of Gossypol. IV. Anhydrogossypol and its Derivatives; J Am Chem Cos 59:1736 (1937)	
	27	Molla et al., Influence of 5-Hydroxytryptamine on the Combination Effect of Lonidamine or Gossypol and Hyperthermia on Ehrlich Tumour In Vivo;Anticancer Res 7:361 (1987)	
	28	Senzer, Hyperthermia: Chemotherapeutic and biologic response Modifications; Strahlenther Onkol 165:729 (1989)	
	29	Tripathy et al., Gossypol Effects on Breast Cancer Oncogene Expression and Membrane Receptor Signal Transduction; Breast Cancer Res Treat 16:160 (1990)	

Examiner Signature	/San Ming Hui/	Date Considered	06/18/2007
*EYAMINER: I	nitial if reference considered, whether or not citation is in conformance with MPEP 60	9. Draw line through c	itation if not in conformance and not

Date

considered. Include copy of this form with next communication to applicant.

considered, Include copy of his form with next communication to applicant.

1 Applicant's unique cistion designation number (optional). A popisant is to place of check mark next if sugsish insignate. Transition is attached.

This collection of information is required by 37 CFR 1.8. The ISC 100 cm of the control of the c Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO	ĺ	Complete if Known
7 Substitute for form 144 av 10	Application Number	10/729,156
INFORMATION DISCLOSURE	Filing Date	12/05/2003
STATEMENT BY APPLICANT	First Named Inventor	Wang et al.
(Use as meny sheets as necessary)	Art Unit	1614
(Use as meny sneets as necessary)	Examiner Name	Hui
Sheet 5 of	Attorney Docket Number	UM-08477

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		Vermel, The Search for Antitumour Substances of Plant Origin; Acta Unio Internationalis Contra Cancrum 20:211 (1964)	
	31	Vermel et al., Voprosy Oncologii 10:88 (1964) (Russian)	
	32	Xu, A Laboratory Investigation on the Antitumor Effects of Gossypol; Med J Jinan Univ 2:39 (1987) (Chinese with translation)	
	33	Zakhidov et al., Ezvestiia Akademii Nauk SSSR Seriia Biologicheskaia 4:694 (1994) (Russian)	
	34	Zhang et al., Comparison of the Killing Effect of Levorotatory, Dextrorotatory and Recemic Gossypol on HeLa Cells; Acta Acad Med Sinicae 7:384 (1985) (Chinese with translation)	
	35	Zhang et al., Analysis of the Possible Mechanism of the Cytotoxic Effect of Gossypol in Mice, Rats and Human Tumor Cell Lines; Acta Acad Med Sinicae 8:486 (1986) (Chinese with translation)	
	36	Zhang et al., In Vitro Antiproliferative Effect of Two New Platinum-Containing Bile Acid Derivatives:Bamet-U2 and Bamet-D3; Anticancer Res 18:4807 (1998)	
$\overline{\mathbf{V}}$	37	Zhang et al., Differential Proliferative Responses to the (-)-enantiomer of Gossypol in Cultured Human Breast Epithelial and Stromal Cells; Proc Amer Assoc Cancer Res 40:4 (1999)	

Examiner Signature	/San Ming Hui/	Date Considered	06/18/2007

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

consequence, include copy or this torm with next communication to applicate.

1 Applicant's ruising culciation designation number (optional). Applicant is not piece o check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) en epiglication. Confidentially is governed by 38 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will very depending upon the individual case. Any comments on the amount of time you require to complete this form endors suggestions for reducing this burden, should be sent to the Chief Information Officer, 12. Patent and Trademark Office, P.O. Bost 1450, Alexandria, VA 22313-1450. DO NOT SERD FEES OR COMPLETED FORMS TO THIS ADDRESS. SERD TO:

Commissioner for Patents, P.O. Bost 1450, Alexandria, VA 22313-1450.